This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. DESCRIPTION (provided by applicant): The Rochester Clinical and Translational Science Award (RCTSA) Program proposes continuation of its dual goals: 1) To organize, support, and expand clinical and translational research at the University of Rochester within an academic home, the University of Rochester Clinical and Translational Science Institute (UR-CTSI), and 2) To integrate and collaborate with regional and national institutions to expand a National Clinical and Translational Research Network. The RCTSA Program has truly transformed the University of Rochester Medical Center (URMC), with the construction of a state-of-the-art Clinical and Translational Science Building, the integration of clinical and translational science into the shared vision for URMC research, a successful system of dynamic governance, expansion of research resources, and enthusiastic participation and leadership in the National CTSA Consortium. To continue this momentum, the UR-CTSI will carry out a number of specific aims. First, three new key functions will be implemented: Public-Private Partnerships, T1 Translation, and Comparative Effectiveness Research. Existing Key Functions will be reorganized and consolidated to provide better support of investigators by an expanded Office of Regulatory Support, a Navigator/Consultation Service, and an Incubator Program consolidating Pilot Studies, Novel Methodologies, and Translational Technologies Key Functions. The CTSI will establish and foster four centers of research excellence across the spectrum of research translation: Center for Human Experimental Therapeutics (T1 Research);Clinical Research Center (T1-3 Research);Center for Research Implementation and Translation (T2-3 research under School of Nursing sponsorship);and Center for Community Health (T2-3 research). A broad range of education, training, and career development programs will continue to meet research workforce needs. The UR-CTSI will be an active participant in the National CTSA consortium with sharing of expertise, methods, data, and curricula. The Upstate New York Translational Research Network (UNYTRN) will be expanded to support the region's biomedical research institutions. Finally, the UR-CTSI will be evaluated through the measurement of rigorous performance outcomes.

Public Health Relevance

(provided by applicant): The UR Clinical and Translational Science Institute (UR-CTSI) will be the focal point for translation of basic discoveries to human applications and clinical trials, and for evidence-based implementation of efficacious clinical practices and effective community strategies. The UR-CTSI will be a model for CTSA involvement of nursing, dentistry, and other disciplines, for engagement of the Rochester community in all aspects of research and for collaboration with regional biomedical institutions in research translation.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
2UL1RR024160-06
Application #
8365025
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Project Start
2011-07-01
Project End
2012-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
6
Fiscal Year
2011
Total Cost
$1,555,403
Indirect Cost
Name
University of Rochester
Department
Public Health & Prev Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Justiniano, Carla F; Temple, Larissa K; Swanger, Alex A et al. (2018) Readmissions With Dehydration After Ileostomy Creation: Rethinking Risk Factors. Dis Colon Rectum 61:1297-1305
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Eichinger, Katy; Heatwole, Chad; Iyadurai, Stanley et al. (2018) Facioscapulohumeral muscular dystrophy functional composite outcome measure. Muscle Nerve :
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Akoh, Christine C; Pressman, Eva K; Cooper, Elizabeth et al. (2018) Low Vitamin D is Associated With Infections and Proinflammatory Cytokines During Pregnancy. Reprod Sci 25:414-423
Loelius, Shannon G; Lannan, Katie L; Blumberg, Neil et al. (2018) The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro. Thromb Res 169:96-104
Loelius, Shannon G; Spinelli, Sherry L; Lannan, Katie L et al. (2018) In Vitro Methods to Characterize the Effects of Tobacco and Nontobacco Products on Human Platelet Function. Curr Protoc Toxicol 76:e46
Barrie, Elizabeth S; Pinsonneault, Julia K; Sadee, Wolfgang et al. (2018) Testing genetic modifiers of behavior and response to atomoxetine in autism spectrum disorder with ADHD. J Dev Phys Disabil 30:355-371
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459

Showing the most recent 10 out of 456 publications